Image source: The Motley Fool.
Zoetis Inc (ZTS -4.32%)
Q3Â 2018 Earnings Conference Call
Nov. 01, 2018, 8:30 a.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Operator
Good day, and welcome to the Third Quarter 2018 Financial Results Conference Call and Webcast for Zoetis. Hosting the call today is Steve Frank, Vice President of Investor Relations for Zoetis. The presentation materials and additional financial tables are currently posted on the Investor Relations section of zoetis.com. The presentation slides can be managed by you, the viewer, and will not be forwarded automatically. In addition, a replay of this call will be available approximately two hours after the conclusion of this call via dial-in or on the Investor Relations section of zoetis.com.
At this time, all participants have been placed in a listen-only mode, and the floor will be open for your questions following the presentation. (Operator Instructions)
It is now my pleasure to turn the floor over to Steve Frank. Steve, you may begin.
Steve Frank -- Vice President of Investor Relations
Thank you. Good morning, everyone, and welcome to the Zoetis third quarter 2018 earnings call. I am joined today by Juan Ramon Alaix, our Chief Executive Officer, and Glenn David, our Chief Financial Officer.
Before we begin, I'll remind you that the slides presented on this call are available on the Investor Relations section of our website and that our remarks today will include forward-looking statements and that actual results could differ materially from those projections. For a list and description of certain factors that could cause results to differ, I refer you to the forward-looking statements in today's press release and our SEC filings, including, but not limited to, our annual report on Form 10-K and our reports on Form 10-Q.
Our remarks today will also include references to certain financial measures, which were not prepared in accordance with generally accepted accounting principles or US GAAP. A reconciliation of these non-GAAP financial measures to the most directly comparable US GAAP measures is included in the financial tables that accompany our earnings press release and in the company's 8-K filing dated today, November 1st, 2018. We also cite operational results, which exclude the impact of foreign exchange.
With that, I will turn the call over to Juan Ramon.
Juan Ramon Alaix -- Chief Executive Officer
Thank you, Steve. Good morning everyone. In 2018, we have been making significant efforts to support the future growth with investment in the business. We're allocating more resources to critical R&D projects, updating and expanding many of our manufacturing capabilities and investing in key areas such as diagnostics with the recent acquisition of Abaxis. We are making good progress integrating Abaxis. Our sales teams are being cross-trained ton Zoetis on Abaxis product lines in the US and Canada, and they are already collaborating on customer accounts.
Outside of the US, we are focused on building a more robust diagnostic testing, and using the existing Zoetis infrastructure to expand our diagnostics sales. The initial feedback on the acquisition has been very good. Our field force has been very positive about the potential of this combination and the more comprehensive solutions they can now bring to our veterinary customers. Early customer responses has been very encouraging. Our core business and investment strategy has Zoetis well-positioned for the future with a diverse portfolio addressing the needs across the continuum of care and a promising pipeline of new products and lifecycle innovations.
As I mentioned last quarter, we have taken a phased filing approach for a new three-way combination parasiticide and we continue making progress. The product will be known by the trade name Simparica Trio, and it will combine sarolaner and two other active ingredients to focus on ectoparasite such as fleas, ticks and mites as well as internal parasites and the prevention of heartworm disease. Our phased regulatory filings are progressing in the US. The safety, efficacy and chemistry manufacturing and control chemical sections are under FDA review. (inaudible) we have submitted the dossier with European Medicines Agency, and subject to regulatory reviews and approval, we would anticipate Simparica Trio coming to market in 2020.
We are also progressing well with our monoclonal antibodies program, targeting pain treatment for dogs and cats. This will strengthen our leadership position for pain in dogs and allow us to expand into cats. I will provide further updates as we move through the regulatory process. Our R&D team also continues to enhance our internal portfolio with the lifecycle innovations and additional problems indications such as the recent expansion of Cytopoint to cover allergies as well as atopic dermatitis in the US, also introducing of leading product brands into newest geographies and new combinations.
Now turning to a few highlights of our third quarter results. Zoetis continued delivering strong revenue growth with 12% operational growth this quarter. Our divest portfolio remains recognition of Zoetis steady and reliable performance with across our major species, markets, and therapeutic areas. Our companion animal products performed very well in the third quarter based on continued growth in our key dermatology brands, new parasiticides, and for the first time, the addition of Abaxis diagnostics portfolio.
We see further growth of (inaudible) for our key dermatology products in 2019. In the US, we expect that portfolio to continue growing, although at a lower rate than 2018. We expect to continue expanding the addressable market in the US, and building awareness of dermatology conditions through online direct-to-consumer campaigns. Internationally, we expect higher growth than in the US, driven by the expansion of the dermatology market, increasing the patient share and the potential introduction of Apoquel in China, pending final regulatory approval. Meanwhile, in livestock products, our swine, poultry and fish portfolios, each delivered double-digit growth with a more modest growth in our cattle business. We expect all our species categories to show growth for the full year 2018 and also for 2019.
For 2019, analysts expect the companion animal and poultry markets to outperform the overall industry growth of approximately 5% excluding the currency impact. Swine is expected to be in line with the market growth and cattle market growth is expected to be more limited.
Turning to profitability, in the third quarter, we achieved 32% operational growth in adjusted net income, thanks to our increased revenue, improved cost structure, and tax reform. In closing, in 2018, we are confident in achieving our improved annual guidance, continuing to grow revenues faster than market and growing adjusted net income faster than revenue.
And with that, let me hand things over to Glenn who will provide more details on our third quarter results and guidance.
Glenn David -- Executive Vice President and Chief Financial Officer
Thank you, Juan Ramon, and good morning everyone. Let me start by highlighting our continued strong performance in both revenue and adjusted net income in the third quarter. As Juan Ramon mentioned, we delivered operational revenue growth of 12%, driven by the performance of our dermatology portfolio, new products, and the addition of Abaxis diagnostics portfolio. Our organic operational revenue growth for the third quarter was 9%, which excludes Abaxis. Operational adjusted net income growth was 32%.
We are confident in delivering our improved financial guidance for 2018 where we are narrowing our revenue guidance at the high end of the range and increasing our adjusted net income and adjusted diluted EPS guidance. While I will not provide formal guidance on 2019 until early next year, I believe our diverse portfolio, core capabilities, and investment strategy will enable us to continue delivering on our value proposition of organically growing revenue in line with or faster than the market and growing adjusted net income faster than revenue.
Now I will talk about the drivers of our Q3 performance, which continued the momentum from the first half of the year. Reported revenue growth was 10 % in the third quarter, which included a negative 2% impact from foreign exchange. Currency depreciation in Brazil was the largest driver of the unfavorability in the quarter. We generated 12% operational revenue growth, balanced across our segments with the US growing 11% and international growing 12% operationally.
Looking at growth by species, companion animal grew 19% operationally and livestock grew 6% operationally. Included in our operational revenue growth of 12% is 3% from Abaxis. Of the 9% organic operational revenue growth, price contributed 4% and volume contributed 5%. New products grew 2% volume with the remaining 3% driven by our key dermatology portfolio. Price contributions of 4% in the quarter are higher than usual and relate to the timing of promotional activities in the third quarter compared to the same period in the prior year. Price contributed 2% over the first nine months of the year, which is more consistent with our expectations.
Adjusted net income grew 32% operationally, driven by revenue growth, gross margin improvements, and a lower effective tax rate. As I already mentioned, our key dermatology portfolio, comprised of Apoquel and Cytopoint, continued to be a significant driver of growth this quarter with sales of $172 million, a 39% increase over the prior year. In the first nine months of the year, we have recognized revenue of $436 million in our key dermatology portfolio with both Apoquel and Cytopoint contributing to the continued success.
Consistent with our expectations for these products, Q2 and Q3 are the peak seasons for dermatitis, so we do anticipate moderated performance in Q4, particularly in the US. We continue to expect sales for this portfolio to exceed $500 million in 2018, and as Juan Ramon discussed, we see continued growth as we move into 2019.
New products also continued to drive growth for Zoetis with Simparica as the primary driver. Simparica generated $43 million of sales this quarter, representing operational growth of 80%over the same period last year. We expect some moderation in Q4 as we moved out of the flea and tick
season in the US. Overall, we continue to be very pleased with the performance of this product in the highly competitive parasiticide market and we expect continued growth both domestically and internationally.
Now, before moving into the segment results, I would like to provide more visibility into the Abaxis' numbers. Included in Zoetis' reported results this quarter are sales of $42 million from legacy Abaxis products since our July 31st acquisition. These sales represent two months of sales in the US, Canada, and Latin America and one month of sales for all other international markets based on our international reporting calendar. Please note that Q3 revenue for Abaxis also includes a destocking of wholesaler inventories that we expect to continue in Q4 as we normalize wholesaler inventories consistent with Zoetis level.
With the acquisition of Abaxis, we're adding a new major product category in our financial statements in our 10-Q filling within the revenue by major product category section called animal health diagnostics. This product category will include the animal health products acquired from Abaxis as well as our legacy diagnostics products, previously classified within other non-pharmaceuticals. The human health diagnostic products acquired from Abaxis will be classified within a new category called contract manufacturing and human health diagnostics.
Now let's discuss Zoetis segment revenues for Q3. Beginning with the US, revenue grew 11% in the third quarter, including Abaxis, which contributed 4%. Including the impact of Abaxis, companion animal grew 20%, while lifestyle grew 1%. Companion animal sales in the quarter were driven our key dermatology portfolio, new products as well as the addition of Abaxis. Certain in-line products declines due to competitive pressure partially offset these increases. Excluding the impact of Abaxis, companion animal growth was 12%.
US dermatology sales grew $121 million for the quarter with both Apoquel and Cytopoint exhibiting significant growth over the same quarter in the prior year. Simparica also had another positive quarter with US sales in the quarter growing 53% over the same period last year. Revenue growth is due to increased in-clinic penetration and market share, and returns on our direct-to-consumer investments. Partially offsetting growth in our companion animal business were declines in Revolution and Clavamox due to competition.
The US lifestyle business continued with strong growth in poultry and swine in the third quarter, partially offset by decline in cattle. In poultry, the Zoetis portfolio of alternatives to antibiotics and medicated feed additives continues to be the primary driver of growth. Favorable market conditions in the layer (ph) market also contributed to growth in vaccines. Swine also had consistent growth in the third quarter, primarily in the feed related to promotional efforts. We also continue to increase market share of Fostera Gold PCV MH, which launched in the first quarter of this year.
In the cattle business, we saw challenges in both the beef and dairy segment related to competition and unfavorable market dynamics. We do expect the cattle market to recover sometime in 2019, however, the impact of weather, herd movements, and producer profitability all play a role in the timing. Overall, the US continues to be a significant growth driver for Zoetis, particularly due to our product diversity and strategic investments, despite some temporary unfavorable market conditions in the cattle business.
Turning now to our international segment, revenue grew 12% operationally in the third quarter with operational growth in companion animal of 18%, and operational growth in livestock of 10%. Companion animal product growth was largely driven by our key dermatology products,
Apoquel and Cytopoint, new products such as Simparica and Stronghold Plus, increased medicalization rates in key international markets, and the addition of Abaxis.
Lifestock products benefited from favorable market conditions, including increasing demand for animal proteins, new products, and the impact of our field force. Our fish business also performed very well this quarter with operational growth of 21%. The strong growth was driven by increased market share of our pancreatic disease or PD vaccine as well as customer adoption of our SRS vaccine in Chile.
Highlighting some key markets for the quarter. In Brazil, sales grew 31% operationally with companion animal growing 48% and livestock growing 26%. Companion animal revenue in Brazil benefited from strong growth in parasiticides with Simparica as the primary driver and a positive return on the direct-to-consumer investment. Livestock benefited from the recovery of sales that were delayed at the end of Q2 due to the national truck drivers' strike. Strong underlying demand, favorable export conditions, and local promotional activities also contributed to growth in the quarter.
In the UK, sales grew 30% operationally. Both companion animal and livestock contributed to this performance with new products primarily driving growth on the companion animal side, and fish driving increases in livestock. Key dermatology products and new parasiticides both performed well in the quarter resulting from field force focus and marketing promotions, which increased pet owner awareness of the brands. In fish, vaccines were the primary driver of growth due to increased market share in our PD vaccines as well as our multivalent vaccine, Alpha Ject Micro 6.
Moving on to China, we had another great quarter growing revenues 15% operationally, largely due to the timing of distributor purchases of our swine products. Companion animal products also continued demonstrating growth, primarily in parasiticides and vaccines.
Australia grew 9% operationally, primarily driven by companion animal and sheep. In companion animal, Simparica and Apoquel increased sales due to the return on our direct-to-consumer investment as well as strength of our in-line portfolio and promotional efforts in the quarter. Sheep products also benefited from continued strength in local market conditions.
Other emerging markets, particularly Vietnam, Argentina, Turkey and India, performed well. Vietnam performed well in livestock, particularly swine due to increased market prices for pork. Argentina and Turkey had broad-based growth across companion animal and livestock, while growth in India was largely due to strength in poultry.
Summarizing international performance, we saw new products, favorable market conditions, and diversity across our portfolio, all contributing to another very strong quarter for our international segment.
Now moving on to the rest of the P&L, I want to cover a few key line items and then discuss guidance for 2018. Adjusted gross margin of 68.7% increased approximately 80 basis points in the quarter on a reported basis. This improvement reflects favorable pricing and the benefit of continued cost improvements and efficiencies in our manufacturing network, which are partially offset by the impact of Abaxis.
Total adjusted operating expenses, including Abaxis, grew 11% operationally versus the same period last year. Adjusted SG&A operational growth was 10%, primarily due to the addition of Abaxis and increased compensation related costs. Adjusted R&D operational growth of 13% reflects increased investments in areas such as monoclonal antibodies for chronic pain and other pipeline programs as well as Abaxis.
The adjusted effective tax rate for the quarter was 19.2%. The tax rate in the quarter is significantly lower than the rate from the comparable 2017 period, due to the favorable impact of US tax reform and discrete items recognized during the quarter. Adjusted net income for the quarter grew 32% operationally through a combination of strong revenue growth, improvement in gross margin, and a lower effective tax rate.
These increases are partially diluted by the impact of Abaxis, which we expect to become mildly accretive in 2019 on an adjusted basis. As previously communicated, we are creating strong operating leverage while investing in strategic areas of future growth for Zoetis, including acquisitions such as Abaxis. Adjusted diluted EPS grew 34% operationally in the quarter versus the same period in 2017.
Now moving to guidance for the full year 2018, our consistent revenue growth, gross margin improvement and returns on strategic investments are allowing us to narrow our revenue guidance toward the high end of the range and raise now our outlook on adjusted diluted EPS. Starting with revenue, we're narrowing the range of our revenue guidance and expect to deliver between $5.75 billion and $5.8 billion in revenue, representing operational revenue growth of 8% to 9%. Excluding Abaxis partial year revenue, which consists of five months of domestic activities and four months of international, the organic operational revenue growth range is 6% to 7%.
Consistent with what I communicated in the last quarter, our full year guidance includes headwinds in Q4 that I want to remind you of as you think about the remainder of the year. Our business in Q4 2017 was very strong. The growth off this higher base will moderate. US livestock is one area where we experienced an exceptionally strong Q4. In addition, the fourth quarter of this year will also include four fewer international calendar days compared to last year, resulting from the change in our accounting calendar implemented this year.
Please note that from an EPS growth perspective, Q4 will be impacted by the timing of cost of sales, which were higher in the first half of 2017 when compared to the second half of 2017 as well as the timing of operating expenses. For SG&A and R&D, we're narrowing guidance toward the high end of both ranges, consistent with our revenue performance and to support investments for future growth.
Our guidance for the adjusted effective tax rate has been lowered to approximately 19% from our previous guidance of approximately 20%. This is primarily due to impact of favorable discrete non-recurring items resulting from the implementation of US tax reform. We continue to anticipate our effective tax rate going forward to be higher due to certain provisions of US tax reform, which will go into effect in 2019.
For adjusted diluted EPS, we are raising and narrowing the guidance and now expect to deliver between $3.08 and $3.13. Our range for reported diluted EPS of $2.81 to $2.90 includes preliminary estimates of certain significant items and purchase accounting for the Abaxis acquisition as well as gain on the sale of our plant health business, which was completed in our international Q4 period.
Finally, we repurchased nearly $550 million of Zoetis shares in the first nine months of the year. We have approximately $450 million remaining under the current multi-year share repurchase plan and remain committed to our capital allocation priorities of internal investments, M&A, and returning excess cash to shareholders. Our guidance for reported and adjusted earnings per share reflects the shares repurchased through the end of Q3.
Now, to summarize before we move to Q&A, we've delivered consistent operational top and bottom line growth in the first nine months of the year with contributions across all core species, therapeutic areas, and geographies. We are narrowing our range of revenue guidance toward the high end of the range and increasing and narrowing our guidance for adjusted net income and adjusted diluted EPS. Our diversity, strategic internal and external investments, and ability to innovate will continue to provide a platform for revenue growth that is in line with or faster than the market.
Now I'll hand things over to the operator to open the line for your questions. Operator?
Questions and Answers:
Operator
(Operator Instructions) We'll take our first question from Jon Block with Stifel. Please go ahead. Your line is open.
Jonathan Block -- Stifel Nicolaus -- Analyst
Great. Thanks, guys. Congrats on the quarter. I'd like to try to jam three questions into one. So the first, on the big three therapeutics, I add that up, over 40% year-over-year. At a high level, how should we think about the rate of growth from these three blockbusters in '19 and '20? I think you said very healthy, but maybe in a diminished rate. So anything more that you can provide there? Second one would be just early feedback from the Abaxis acquisition. How should we think about sales force retention? And then have you kicked off any bundling in terms of price? And lastly, Glenn, just the price of 4% in the quarter, I just want to be clear there, we should think of that more as one-time due to the year-ago comp. Thanks, guys.
Juan Ramon Alaix -- Chief Executive Officer
Thank you, Jon. Glenn will answer the first question. I will cover the Abaxis question and then Glenn also will provide the comments on the 4% price increase in the quarter.
Glenn David -- Executive Vice President and Chief Financial Officer
So Jon, when you look at the big three, and I assume you're mentioning Apoquel, Cytopoint and Simparica, we've had very strong growth in the quarter and year-to-date. As we look forward into 2019, 2020, we do still see opportunities for growth for all those products. So particularly with our dermatology portfolio, we see continued growth in the US, albeit at a slower rate as we have significant penetration in terms of patient share there. We're up to 63% already. We do see further opportunity to continue grow the market there as well.
We also see a very strong opportunity internationally where the penetration isn't quite at that level yet. So we do see continued growth internationally in Apoquel and Cytopoint as well. And Simparica, we continue to see very strong performance, continued adoption, and we think that growth will continue into the 2019 and '20 as well, but again, probably at a slower rate, and also the impact of competition and new products that may come into that category may also impact growth going forward.
Juan Ramon Alaix -- Chief Executive Officer
Okay. Thank you, Glenn. In terms of the Abaxis integration, well, the retention of the field force, I think, is not -- I can describe as a 100% retention, and not only it's about retention. It's about the feedback that we are getting from the field force from Abaxis, which is extremely positive. They are expressing the excitement of the opportunity now to be supported by a larger company, by much more pressures (ph) in our field and the combination of the two portfolios is something that can create significant opportunities.
I think it's too early to discuss about bundling. Definitely we see the opportunity of combining the diagnostic portfolio of Abaxis, the diagnostic portfolio of Zoetis and also the rest of the portfolio of medicines. And it's something that is a work in progress. We see that diagnostic medicines vaccines are very much integrated in the clinics. So we expect that this will represent a significant opportunity in the future.
Glenn David -- Executive Vice President and Chief Financial Officer
And Jon, in terms of the price for the quarter, so like you say, the 4% is more of a one-time impact for the quarter. The year-to-date number of 2% is much more in line with what we typically expect to be able to generate from price.
Juan Ramon Alaix -- Chief Executive Officer
Next question please.
Operator
And we'll take the next question from Alex Arfaei with BMO Capital Markets. Please go ahead.
Alex Arfaei -- BMO Capital Markets -- Analyst
Okay. Thank you very much for taking my questions and congratulations on the progress. First, just to follow up on the topic dermatitis, I think one of your competitors reported data with their IL-31 recently. I'm referring to Kindred. Just wondering if you had any thoughts there whether it's on that product, or just in general how you see the competitive landscape evolving here. I'm sure your success hasn't gone unnoticed. The second, could you please break out Apoquel, Cytopoint and Simparica by US and ex-US? And finally if I may, Juan Ramon , I missed your comments about 2019 expectations for livestock species. Could you please clarify that and any additional color would be appreciated. Thank you.
Juan Ramon Alaix -- Chief Executive Officer
Thank you, Alex. Good morning. So let me discuss about the potential composition of our dermatology portfolio. Definitely, and this is something that we already communicated in previous call, that over time we expect competitors coming into this attractive market. It's a market that has been basically created by Zoetis. In the same way that many years ago, we also created the pain market for dogs, and even after many years and many new entrants, but still Rimadyl remains the leading brand in terms of pain for dogs. So we are expecting competition, but we also expect that we have a very strong position with the combination of Apoquel and Cytopoint and products that have been responding extremely well to the needs of veterinarians and also the needs of dogs, and we are very confident that this product will continue growing. New competition also will expand the market and we'll also benefit of this market expansion from our leadership position. Glenn will discuss about the breakdown between dermatology products Simparica, US, international, and also I will be covering the expectations for our livestock in 2019.
Glenn David -- Executive Vice President and Chief Financial Officer
So just to break out the numbers, so for derm for Q3, we had total sales of $172 million. $121 million of that came from the US with $51 million coming from international. Breaking out Apoquel, we had total sales of $134 million, US at $88 million; international at $45 million. You can then do the math for Cytopoint, the difference between the two. For Simparica, we had total sales of $43 million in the quarter with the US at $26 million and international at $17 million.
Juan Ramon Alaix -- Chief Executive Officer
So the comments I provided for 2019 in terms of livestock was related -- were related to the market and not specific to our projections for 2018 livestock at Zoetis. What I said is that the market, expect that probably, will be growing faster than this 5%, which is expected growth for the overall animal health industry. Swine will be in line with the market and cattle will be much more modest growth. And this is something that at this point we're not yet providing the specifics of our growth in 2018, but we expect that we'll be more or less in line with the market expectations. Next question.
Operator
The next question comes from Louise Chen with Cantor Fitzgerald. Please go ahead.
Louise Chen -- Cantor Fitzgerald -- Analyst
Hi, thanks for taking my questions. So my first question here was just back onto the cattle here. Can you just give more specifics as to what is going to actually drive the recovery in cattle in 2019? And then the second question is just on opportunities for growth and operating margin expansion in 2019 and beyond. If you still see anything beyond what you've already said, and if so, where these could come from? Thank you.
Juan Ramon Alaix -- Chief Executive Officer
Thank you, Louise. We expect, as I said, in 2019, a modest growth in cattle for the animal health industry. We see that the prices for dairy are improving. We expected this improvement to be seen in the second half of 2018, it's taking longer, but now there are indications that these prices are recovering in the US and also recovering in the international market. So we are more optimistic about dairy in 2019. In 2018, we also expect a small growth -- very little growth in terms of a number of markets, in the beef section of the cattle, and combining all these elements, we expect some recovery of cattle in 2018, but as I said, cattle is expected to grow at a modest growth.
Glenn David -- Executive Vice President and Chief Financial Officer
And Louise, in terms of margin expansion, first, I'll just continue to say that we're really not managing to any particular margin, but really we are managing for long-term cash flow growth and value. When you look forward in terms of 2019 and 2020, we've previously articulated that we expect to get gross margin expansion of about 200 basis points by 2020 with 2017 being the starting point for that. So our cost of goods as a percent of sales at that point was about 33%. We've guided 2018 to be approximately 32%, and we do expect continued improvement in both 2019 and 2020.
As we move forward, we also do expect to be able to get some leverage from operating expenses, but in 2019, in particular, as we continue to integrate Abaxis and build to make sure that we're supporting that business, that expansion may not be as strong as it may be moving forward in 2020 and beyond. But between the combination of the gross margin expansion and being able to grow expenses at a slower rate than revenue, we do expect to be able to get margin expansion moving forward.
Juan Ramon Alaix -- Chief Executive Officer
Thank you, Glenn. Next question please.
Operator
Our next question is from Kevin Ellich with Craig-Hallum. Please go ahead.
Kevin Ellich -- Craig-Hallum Capital -- Analyst
Good morning. Thanks for taking my questions. I guess, could we start off with capital allocation? You guys have -- now that you've done with the Abaxis acquisition, wondering what else we should be thinking about in terms of how you plan to use the capital aside from the share repurchases. And then can you also comment on the pipeline, Juan Ramon? Appreciate the comments on Simparica Trio and when you expect it. What about Europe? Are we going to see it approved in Europe before the US? And then congrats on winning the Deming Cup for operational excellence. Thanks.
Juan Ramon Alaix -- Chief Executive Officer
Thank you, Kevin. In terms of our capital allocation, we are not changing the previous capital allocation communication. So definitely we see and we continue seeing opportunities in terms of investing internally. We are increasing our allocation to R&D. We communicated that also we are expanding and increasing the capabilities in manufacturing. And we see opportunities in commercial, and in 2018, '19, the opportunities definitely will be in diagnostics and will be an expansion of our presence in the international market. So we continue investing internally and the return of these investments has been extremely positive and we'll continue making sure that we have the resources to generate long-term growth.
In terms of BD, it's the second priority in terms of capital allocation. We just completed the acquisition of Abaxis. We also had some of our minor acquisitions, Smartbow, that is also -- a company that will be providing sensors and also the operability for more data analytics, digital in the dairy farms. And it's an area that we are also very interested ensuring that we are developing the internal capabilities in terms of digital, data analytics there to provide this value to our customers. And we'll continue with returning the excess capital to our shareholders. It will be through dividends, it will be through buying shares back. Nothing has changed, and definitely we still see opportunities of, as I said, continue investing internally, in defining external opportunities, and returning this excess capital.
In terms of the pipeline, well, Simparica Trio has been filed in both, the US and also Europe. When this will be coming to the market, it's yet to be seen because it's depending on the regulators, but definitely we expect that Simparica Trio will be in the market sometime in 2020. Who will be first? It's to be seen.
There are some other products that also we'll see even earlier than 2019. We are also expecting that in the US, we'll have lifecycle relation with Revolution Plus and combining Revolution Plus active ingredient with bigger combination of other agents that we will expand the protection not only to fleas and ticks, but making stronger for ticks. And this is something that -- we expect that this Revolution Plus coming into the market in 2019. And we'll continue also bring in some other products in 2019 in the US and also international markets, especially lifecycle innovation.
I also mentioned that we are expecting the approval of Apoquel in China. Again, so it's subject to regulatory approval, but it can be some time in 2019, and this will also help us to continue growing Apoquel or the derm portfolio for Zoetis. And China, and now, it's one of our top markets for companion animals within Zoetis. So it's probably a good opportunity that we see, the introduction of Apoquel in this market. Next question?
Operator
Our next question is from Erin Wright with Credit Suisse. Please go ahead.
Erin Wright -- Credit Suisse -- Analyst
Thanks. A couple of questions here. You mentioned some destocking as it relates to Abaxis, but can you provide any sort of metrics on the integration process there and traction you're seeing in terms of end customer instrument placement trends or consumables growth? And as we think about modeling out the diagnostics segment that you'll be breaking out, should we consider that a double-digit grower when studying your own diagnostics portfolio?
And then the second part of my question is, how you think about a potentially kind of evolving supply chain in pet medications, do you think that it is rapidly evolving or evolving to some extent that consumers have more choice and veterinarians have more choice? And what do you think about broader implications, newer concepts such as Vets First Choice and your ability to realize price thereon? Thanks.
Juan Ramon Alaix -- Chief Executive Officer
Thank you, Erin. So in terms of Abaxis pro forma, I think it's the integration or the closing of Abaxis has been at the mid of this quarter. I think it's probably a little bit too early to provide full details of the different elements of the diagnostic implementation in the clinics. This is something that we'll discuss what will be the level of information that we'll be providing in the future, and maybe we can have this discussion in the fourth quarter when we have the full quarter ready for reporting and having all the elements under control by Zoetis. Glenn will be talking about the destocking question that you raised.
Glenn David -- Executive Vice President and Chief Financial Officer
Yeah. So just to give a little more color into the Abaxis number, so we referenced that we had $42 million of sales in Q3. Just a reminder, that includes two months of US and one month of international. So it's a partial quarter. Of that $42 million, there is also $7 million related to human health diagnostics. So the animal health diagnostics piece of that $42 million was $35 million.
To get to your question on growth for the quarter a little bit, Erin, if you take some of the pro forma information and then put that together with what I just referenced in terms of the $35 million, again, it's not a 100% audited or accurate because we're piecing together different pieces of information, but you would get to mid-single digit growth for the quarter for the legacy Abaxis business. Now, that does also include the destocking that I referenced, which we do expect to continue into Q4, but if you were to adjust for that destocking, we get to double digit growth in the Abaxis portfolio, which we do expect to continue moving forward with double-digit growth rates.
Juan Ramon Alaix -- Chief Executive Officer
And Erin, what we expect from animal health diagnostics growth trend long term is that we'll be growing faster than the animal health core business medicines. And I think it has been in the past growing at 7%, 8%. We also expect that in the future we'll be growing higher than the 5%. And where we see significant opportunities for growth is in international markets, in where we are now expanding our presence and we are convinced that we'll have a significant opportunity to penetrate in these markets.
You also asked about the US changes in the distribution retail channel, talking about Vets First Choice or internet pharmacy. Well, that's definitely -- it's a lot of changes in these segments, companion animal in the US. We see some of the changes also having the positive impact of expanding the market, having much more access for pet owners, at the same time, the opportunity also to increase compliance. But at the same time, we are convinced that veterinarians will remain at the center of healthcare decisions, especially in areas that will require prescription or the intervention of veterinarians with injectables or vaccination or acute treatment in the companion animals. And we'll be continue supporting veterinarians really to deliver value to our pet owners.
Next question?
Operator
Our next question is from Michael Ryskin with Bank of America Merrill Lynch. Please go ahead.
Michael Ryskin -- Bank of America Merrill Lynch -- Analyst
Thanks. Congrats on the quarter, guys. I have a couple of questions, I want to roll it into one, but if you can be focused on some of the innovation of the portfolio, you talked about the additional indications for Cytopoint, the allergic dermatitis. Can you give any sense of how much that expands the potential for that product near term and both as we go into 2019 and 2020? And then regarding some of the other innovation, the lifecycle extensions in Draxxin and Vanguard, some of the work you mentioned, the focus on the pain monoclonal antibody, just to get a sense of how big of a contributor this could be in 2019, 2020 as some of these new products come in? And then along that line, one last one is, we saw some news reports that the USDA was potentially granting you license for an African swine fever vaccine. It's in an open comment period. Can you talk about the potential for that market? Obviously there is a lot of talk in the swine markets about the disease outbreaks there. So any sense of timing or potential impact? Thanks.
Juan Ramon Alaix -- Chief Executive Officer
Thank you, Mike. So let me cover the question on the additional label indication for Cytopoint. So in allergy, there are four main reasons for these conditions. So one is related to fleas; the other one is food, and the third one is the environment. Anything which is not in these three areas, it's described as atopic. Now, Cytopoint also have the indication of allergy, not only atopic indication, and this will help us really to promote all the indications of Cytopoint.
We are not expecting significant revenues because of that, but definitely, it's an area that, in our opinion, veterinarians have been using Cytopoint based on their own understanding of the needs. But the fact that we'll be now promoting a broader label will always help, but we don't expect a significant incremental revenue. We expect that the market in the US still has a potential for expansion, and also we expect that our patient share also can increase with the right interactions with veterinarians and the right communication with the pet owners. And this is applicable to the US and also international.
In terms of pipeline contribution in the near term, well, in the near term, if we discuss about near term 2018, so the pipeline will be mainly related to lifecycle innovation. We'll always be producing some vaccines, new products, but we expect a significant introduction of new products in 2020, and we'll have the opportunity to discuss in February the details of our guidance for 2019 and also how we've seen '18 in terms of the difference sources of our growth, our product portfolio, new product introduction, and also our price.
You also asked about the African swine fever and the collaboration with the USDA. Well, this is something that it would take several years to see a vaccine in the market to protect pigs against the African swine fever. Definitely it's an area that has significant impact, and we have seen the impact now in China, and also even in some other markets, it's affecting the production of pork. But what I think -- it's even more important that what is the short-term opportunity for developing a vaccine to protect pigs against the African swine fever. It's the confirmation that Zoetis is the banner of choice with the USDA and many other institutions when we need to bring new vaccines into the market, and this is, in my opinion, what is important at this moment in the collaboration that we are establishing between us and USDA. Next question.
Operator
The next question is from John Kreger with William Blair. Please go ahead.
Jonathan Kaufman -- William Blair -- Analyst
Hi, good morning. This is Jon Kaufman on for John Kreger. So a question on the monoclonal antibody products. Is there anything more you can tell us? What stage of the development process are they in and when do you expect them to come to market? Thank you.
Juan Ramon Alaix -- Chief Executive Officer
Well, I think it's too early to indicate when the product will be in the market. So what I can tell you is that we are making very good progress. So we have several products for both dogs and cats. We are very optimistic about these products reaching their markets, and as I said, I will provide to you more updates as we start the process of filling the dossier into the FDA and also the European agencies. And then when we have that information, then we'll be providing more details of when we plan to have the products into the market.
Next question.
Operator
The next question is from Chris Schott with J.P. Morgan. Please go ahead.
Chris Schott -- J.P. Morgan -- Analyst
Great. Thanks very much for the questions. Just one coming back to some of the earlier comments on OpEx going forward and expense growth. You've obviously stepped up spend this year, supporting the pipeline and the new launches. Sounds like 2019 might be another year of investment with Abaxis. I guess, my question is once we get beyond that spend, should we think about OpEx growth slowing back down to more inflation type growth that we've seen historically for the company? Or are we in a sustained period here where we should think about OpEx growth above inflation, maybe closer to top line, just given the variety of new products that you seem to have targeted for the next few years?
My second question was just on the Simparica Trio, and maybe just you can step back, maybe just put in context how much larger of an opportunity do you see for that product relative to Simparica today as we just think about that 2020 and beyond opportunity? Thank you.
Juan Ramon Alaix -- Chief Executive Officer
Thank you, Chris. Well, I will provide some general comments about OpEx and then also Glenn will provide more details. So we have seen that 2018, maybe also '19 are years in where we are building some additional capabilities in our commercial infrastructure. They have been also two years where we see additional opportunities to invest in R&D and this is driving a higher growth in terms of operating expenses than in previous years. In the long term, I think we'll remain, well, in line with the previous communications that operating expenses will be growing in line with inflation. But it is also true that we have seen significant changes in our business. The, well, infusion or addition of capacities, we also included some other areas in where we need some additional capabilities, and there are now new opportunities that we have seen also in digital and also in terms of data analytics. All these is, well, creating the need of further investments, but as I said, it's something that will be as a temporary, and then over time, moving into the long term growth in line with inflation.
Glenn, you want to add some additional comments here?
Glenn David -- Executive Vice President and Chief Financial Officer
Yeah. The only thing I'd add particularly for 2019, as you look at it, I mean, one of the key drivers of thee expense growth for 2019 will be the fact that we'll have a full 12 months of the Abaxis portfolio and expenses supporting that portfolio in 2019 versus only a partial year this year. And we'll also still be in the build stage for some of the diagnostics field force that we're building in both the US and international. As Juan Ramon said, once we move forward into 2020, we would expect particularly the G&A line to then trend much more in line with inflation and sterling in particular, we would expect expenses to be slower than revenue growth from a sterling perspective as well. R&D, we'll continue to look at the opportunity and to the extent that there are opportunities to drive future short, medium, and long-term growth, we'll make the right investments from an R&D perspective.
Juan Ramon Alaix -- Chief Executive Officer
So in terms of Simparica Trio and incremental opportunity compared to Simparica, we are very pleased with the performance of Simparica. So we are now on the nine month close to $150 million, $144 million. But still we are significantly under-represented in the oral parasiticide market in where NexGard or Bravecto are generating much more significant sales. And one of the reasons were that we were, well, several years behind the competitors in terms introducing these products. We are confident that with the Simparica Trio, we'll be bringing a product that would be highly competitive and also we'll have the opportunity to capture part of the revenues which are today on internal parasiticide and also heartworm provided by other products. So the opportunity in Simparica Trio is to capture higher share in terms of the overall market of oral parasiticides and expanding to internal parasiticides. So we'll provide in the future when we have probably closer to the launch what can be the expectations of Simparica Trio. Next question.
Operator
The next question is from Kathy Miner with Cowen and Company. Please go ahead.
Kathleen Miner -- Cowen and Company -- Analyst
Thank you. Good morning. Just two quick questions on companion animal. First, in the past, you've estimated the US market penetration of your derm products is around 59%. Is that good or has that increased? And the second question is, also on companion animals, derm market trends have been very strong. How should we be thinking about the -- underlying the base business? Is that flattish or growing slightly going forward? Thank you.
Juan Ramon Alaix -- Chief Executive Officer
So thank you, Kathy. So you're correct. So the 59% share, it was related to patient share for Apoquel, Cytopoint. This was in previous quarters. Now we have increased to 63% in the US and we are significantly lower in international markets. And again, so international markets is where we see the opportunity of, first, expanding the dermatology market and also increasing our penetration with the market share. You also asked about the base business excluding the -- I guess that's Apoquel, Cytopoint, Simparica. This is -- I guess this is the question. Maybe Glenn, you can answer that.
Glenn David -- Executive Vice President and Chief Financial Officer
Yeah. So when you look at the base business in the US that you exclude the derm products, volume growth is declining. That is partially offset by some positive increase in price, but overall volume growth is declining, and that is driven by some competitive pressures that we're seeing on some of our more established products such as the Revolution and Clavamox as they face competition A, from other new products, but also from generic competition. But the impact that we're seeing there is very much in line with what we expect from a long-term perspective once we lose exclusivity in terms of the 20% to 40 % over an extended period of time.
Juan Ramon Alaix -- Chief Executive Officer
Next question please.
Operator
The next question is from David Risinger with Morgan Stanley. Please go ahead.
David Risinger -- Morgan Stanley -- Analyst
Yes. Thanks very much and congrats on the performance. I have a couple of questions related to the Trio opportunity. The first is, have you filed all of the components of the application with the FDA? Second, I believe that, Juan Ramon, you said 2020, which I believe is a delay from the prior comment for the second half of '19 approval and launch. Could you comment on that? And third, do you have 100% heartworm protection in the product? Thank you.
Juan Ramon Alaix -- Chief Executive Officer
Thank you, Dave. Let me confirm that Simparica Trio has been filed with all the different sections in the FDA. And well, I thought that in previous communications, we were saying that we're expecting Simparica Trio to be in the market in 2020, and we can maybe check if there was any confusion here, but I think it's -- I want to confirm that we expect this product in 2020. And let me -- I think we are very confident that the product Simparica Trio will have full protection for heartworm, but let me confirm with our scientists what will be the level of protection in terms of a percentage, but we are very confident that efficacy of the product for internal and external will be excellent. So this is one of the reasons why we are confident that the product will have a significant opportunity once it's launched into the US and also in international markets. Let me say that in international markets, maybe the opportunity is lower than the US because heartworm outside of the US is less prevalent. So the biggest opportunity for Simparica Trio will be in the US.
Next question?
Operator
It does appear we have no further questions. I'll return the floor to Juan Ramon Alaix for closing comments.
Juan Ramon Alaix -- Chief Executive Officer
Thank you for your attention. We are very pleased with the results of the third quarter, and as I said, extremely confident in our guidance for total year 2018 that has been growing over time, and now we have provided an increase in terms of adjusted net income for a total year. Thank you for your attention.
Operator
And this will conclude today's program. Thanks for your participation. You may now disconnect. Have a great day.
Duration: 62 minutes
Call participants:
Steve Frank -- Vice President of Investor Relations
Juan Ramon Alaix -- Chief Executive Officer
Glenn David -- Executive Vice President and Chief Financial Officer
Jonathan Block -- Stifel Nicolaus -- Analyst
Alex Arfaei -- BMO Capital Markets -- Analyst
Louise Chen -- Cantor Fitzgerald -- Analyst
Kevin Ellich -- Craig-Hallum Capital -- Analyst
Erin Wright -- Credit Suisse -- Analyst
Michael Ryskin -- Bank of America Merrill Lynch -- Analyst
Jonathan Kaufman -- William Blair -- Analyst
Chris Schott -- J.P. Morgan -- Analyst
Kathleen Miner -- Cowen and Company -- Analyst
David Risinger -- Morgan Stanley -- Analyst
Transcript powered by AlphaStreet
This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.
